A.riddell

Biography

Dr. Alastair Riddell joined Cristal Therapeutics Supervisory Board as non-executive director in December 2015. Dr. Riddell has over 30 years experience in the pharmaceutical, life science and biotech industries. After 10 years directing clinical trials of oncology and intensive care products for Lederle (now part of Pfizer), Celltech (now part of UCB) and Centocor (now part of J&J), he spent 5 years managing sales and marketing for monoclonal antibodies, oncology and imaging products for Centocor and Amersham International (now GE Healthcare). This led to 12 years as a biotech CEO for Pharmagene, Paradigm Therapeutics and Stem Cell Sciences, in these roles he was the principal involved in an IPO on UK’s main list, trade sales to international companies and significant fund raising rounds. He was also a Board member of the BIA for 10 years and Chair or senior independent director of several other biotech companies, mostly University spin outs. He was recently Chairman of Silence Therapeutics (AIM listed). He has had several roles in UK government initiatives related to medical school funding, promoting pharmaceutical company and NHS cooperation and funding healthcare company projects. He is currently Chairman of Definigen Ltd a Cambridge University spin out and AzurRx Biopharma, a New York and France based biotech company. He began his career as a medical doctor with 6 years experience in a variety of hospital specialties and in general practice.

Research Interest

pharmaceutical, life science and biotechnology